Invest in Psilocybin Therapy with Compass Pathways Stock

Perhaps it was an old urban myth, but everyone used to say that if the cops bust you with mushrooms, just dump them on the floor of your car. As long as they’re not in baggies, you’re cool. We’re not sure if that’s sound advice or not, but soon it may be a moot point. That’s because mushrooms – and psychedelics in general – are quickly becoming recognized for their therapeutic powers.

In last year’s piece on 7 Psychedelic Therapy Companies Addressing Mental Health, we briefly covered a company called Compass Pathways (CMPS) that’s looking to create psilocybin therapeutics. Given the significant level of interest we’ve seen from investors surrounding this topic, we’re going to take a closer look at Compass Pathways stock.

About Compass Pathways Stock

Founded in 2016, Compass Pathways is located on the outskirts of Karl Pilkington’s stomping grounds – Manchester, England – where the company managed to raise just over $116 million